23 August 2018

ASX ANNOUNCEMENT

PREVENT Trial Results Published - Outstanding Initial Data

Brisbane, Australia - ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), is pleased to announce the publication of the first of a number of manuscripts from data obtained from the PREVENT trial.

The authors from the PREVENT trial concluded that L-Dex® is very sensitive in the assessment of sub-clinical lymphoedema in patients with a history of breast cancer.

The paper also supports the recommendation for an aggressive measurement protocol consisting of an L-Dex® assessment every three months, especially during the first 6 to 12 months post-surgery to facilitate identification of sub-clinical lymphoedema.

Richard Carreon, Managing Director and CEO of ImpediMed said, “This publication significantly adds to our growing body of clinical evidence necessary to obtain payment from private payers. This publication will also be used as part of our submission to the NCCN guidelines to establish BIS as the standard of care for monitoring patients at risk of developing lymphoedema.”

A link to the article can be found here: https://www.liebertpub.com/doi/pdf/10.1089/lrb.2017.0070

Richard Carreon
Managing Director & CEO

Media Contact:
Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.
For more information, visit www.impedimed.com.